Global Closed Drug Transfer Systems Revenue Valued At 382.47 M USD In 2017
Warning: date() expects parameter 2 to be long, string given in /www/wwwroot/www.globalinforesearch.com/static/themes/default/info_detail.php on line 32
Global revenue of Closed Drug Transfer Systems was valued at 382.47 M USD in 2017, and is forecast to reach 1640.16 M USD by the end of 2025. Millions of healthcare workers are exposed to chemotherapy and other hazardous drugs annually. Studies have shown that exposure to these hazardous drugs can cause serious health problems, “such as cancer, reproductive and development problems and other adverse effects that can be irreversible even after low-level exposures,” according to the Occupational Safety & Health Administration (OSHA), National Institute of Occupational Safety & Health (NIOSH), and Joint Commission. So, Potential market is huge in the future.
Now some companies see the future profit, they started to expand their investment on Closed Drug Transfer Systems to occupy the market share.
For Example, Equashield, a leading provider of Closed System Transfer Devices (CSTDs) for the safe and simple handling of hazardous drugs, today held a groundbreaking for a new manufacturing plant. The company will invest an estimated $30 million to build the new plant to meet the growing market demand for manual and automated hazardous drug compounding devices.
Corvida Medical has leveraged about $6 million in non-dilutive federal, state, and private awards and secured $2.25 million in Series A proceeds to achieve critical milestones to date. Corvida completed a $10.9 million Series B over a series of tranches with the final closing in mid-2015 and is now seeking a convertible note investment, with $3.8 million already committed and on track to close Q1 2016. Management anticipates a $7-10 million Series C late 2016/early 2017 (including the convertible note proceeds) with funds to be used to scale-up manufacturing capacity, build-out production inventory, add personnel, and fuel revenue growth. Corvida has an opportunity to achieve cash flow positive within 2 years of launch (on roughly $1 million in monthly sales), and a realistic opportunity to ramp revenues to $20-30 million within 2-3 years!
Meanwhile, the government's attitude has a huge impact on the market. However, now, only the United States and some European and Asia countries have promulgated relevant policies. But, even in these countries, the level of promotion is still relatively low.
USA dominated the Closed Drug Transfer Systems, and is the largest production base. In addition to USA, there are some other production areas, such as Europe. In consumption market, North America is the mainly consumption regions due to the bigger demand of downstream applications. In 2017, North America occupied 76.76% of the global consumption value in total. But the above forecast is based on the current policy. If a country suddenly made the relevant policies, then the entire market will change.